Literature DB >> 9399847

Software and database for the analysis of mutations in the VHL gene.

C Béroud1, D Joly, C Gallou, F Staroz, M T Orfanelli, C Junien.   

Abstract

VHL is a tumor suppressor gene localized on chromosome 3p25-26. Mutations of the VHL gene were described at first in the heritable von Hippel-Lindau disease and in the sporadic Renal Cell Carcinoma (RCC). More recently, VHL has also been shown to harbor mutations in mesothelioma and small cell lung carcinoma. To date more than 500 mutations have been identified. These mutations are mainly private with only one hot spot at codon 167 associated with pheochromocytoma. The germline mutations are essentially missense while somatic mutations include deletions, insertions and nonsense. To standardize the collection of these informations, facilitate the mutational analysis of the VHL gene and promote the genotype-phenotype analysis, a software package along with a computerized database have been created. The current database and the analysis software are accessible via the internet and world wide web interface at the URL:http://www.umd.necker.fr

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9399847      PMCID: PMC147207          DOI: 10.1093/nar/26.1.256

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  26 in total

1.  Identification of a novel protein (VBP-1) binding to the von Hippel-Lindau (VHL) tumor suppressor gene product.

Authors:  H Tsuchiya; T Iseda; O Hino
Journal:  Cancer Res       Date:  1996-07-01       Impact factor: 12.701

2.  APC gene: database of germline and somatic mutations in human tumors and cell lines.

Authors:  P Laurent-Puig; C Béroud; T Soussi
Journal:  Nucleic Acids Res       Date:  1998-01-01       Impact factor: 16.971

3.  The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins.

Authors:  A Pause; S Lee; R A Worrell; D Y Chen; W H Burgess; W M Linehan; R D Klausner
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

4.  Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan.

Authors:  B Zbar; T Kishida; F Chen; L Schmidt; E R Maher; F M Richards; P A Crossey; A R Webster; N A Affara; M A Ferguson-Smith; H Brauch; D Glavac; H P Neumann; S Tisherman; J J Mulvihill; D J Gross; T Shuin; J Whaley; B Seizinger; N Kley; S Olschwang; C Boisson; S Richard; C H Lips; M Lerman
Journal:  Hum Mutat       Date:  1996       Impact factor: 4.878

5.  Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas.

Authors:  T Shuin; K Kondo; S Torigoe; T Kishida; Y Kubota; M Hosaka; Y Nagashima; H Kitamura; F Latif; B Zbar
Journal:  Cancer Res       Date:  1994-06-01       Impact factor: 12.701

6.  Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma.

Authors:  J M Whaley; J Naglich; L Gelbert; Y E Hsia; J M Lamiell; J S Green; D Collins; H P Neumann; J Laidlaw; F P Li
Journal:  Am J Hum Genet       Date:  1994-12       Impact factor: 11.025

7.  p53 gene mutation: software and database.

Authors:  C Béroud; F Verdier; T Soussi
Journal:  Nucleic Acids Res       Date:  1996-01-01       Impact factor: 16.971

8.  Mutations of the VHL tumour suppressor gene in renal carcinoma.

Authors:  J R Gnarra; K Tory; Y Weng; L Schmidt; M H Wei; H Li; F Latif; S Liu; F Chen; F M Duh
Journal:  Nat Genet       Date:  1994-05       Impact factor: 38.330

9.  Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype.

Authors:  P A Crossey; F M Richards; K Foster; J S Green; A Prowse; F Latif; M I Lerman; B Zbar; N A Affara; M A Ferguson-Smith
Journal:  Hum Mol Genet       Date:  1994-08       Impact factor: 6.150

10.  Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas.

Authors:  H Kanno; K Kondo; S Ito; I Yamamoto; S Fujii; S Torigoe; N Sakai; M Hosaka; T Shuin; M Yao
Journal:  Cancer Res       Date:  1994-09-15       Impact factor: 12.701

View more
  28 in total

1.  DNA copy number changes in Schistosoma-associated and non-Schistosoma-associated bladder cancer.

Authors:  W El-Rifai; D Kamel; M L Larramendy; S Shoman; Y Gad; S Baithun; M El-Awady; S Eissa; H Khaled; S Soloneski; M Sheaff; S Knuutila
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

Review 2.  Genetic predisposition to kidney cancer.

Authors:  Laura S Schmidt; W Marston Linehan
Journal:  Semin Oncol       Date:  2016-09-22       Impact factor: 4.929

3.  Nephron sparing surgery in von Hippel-Lindau associated renal cell carcinoma; clinicopathological long-term follow-up.

Authors:  C A Jilg; Hartmut P H Neumann; S Gläsker; O Schäfer; C Leiber; P U Ardelt; M Schwardt; W Schultze-Seemann
Journal:  Fam Cancer       Date:  2012-09       Impact factor: 2.375

4.  Arginine refolds, stabilizes, and restores function of mutant pVHL proteins in animal model of the VHL cancer syndrome.

Authors:  Merav D Shmueli; Limor Levy-Kanfo; Esraa Haj; Alan R Schoenfeld; Ehud Gazit; Daniel Segal
Journal:  Oncogene       Date:  2018-09-07       Impact factor: 9.867

5.  Genotype phenotype correlation in Asian Indian von Hippel-Lindau (VHL) syndrome patients with pheochromocytoma/paraganglioma.

Authors:  Nilesh Lomte; Sanjeet Kumar; Vijaya Sarathi; Reshma Pandit; Manjunath Goroshi; Swati Jadhav; Anurag R Lila; Tushar Bandgar; Nalini S Shah
Journal:  Fam Cancer       Date:  2018-07       Impact factor: 2.375

6.  VHL P25L is not a pathogenic von Hippel-Lindau mutation: a family study.

Authors:  Rachel K Pettman; Amy Crowley; Christie Riddell; Mark D Ludman
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

7.  The VHL-dependent regulation of microRNAs in renal cancer.

Authors:  Calida S Neal; Michael Z Michael; Lesley H Rawlings; Mark B Van der Hoek; Jonathan M Gleadle
Journal:  BMC Med       Date:  2010-10-21       Impact factor: 8.775

8.  A vitronectin M381T polymorphism increases risk of hemangioblastoma in patients with VHL gene defect.

Authors:  Jing-Shan Huang; Chih-Ming Lin; Yu-Che Cheng; Kun-Long Hung; Chih-Cheng Chien; Shao-Kuan Chen; Chih-Ju Chang; Chan-Wei Chen; Chi-Jung Huang
Journal:  J Mol Med (Berl)       Date:  2009-03-14       Impact factor: 4.599

Review 9.  Diversity of degradation signals in the ubiquitin-proteasome system.

Authors:  Tommer Ravid; Mark Hochstrasser
Journal:  Nat Rev Mol Cell Biol       Date:  2008-09       Impact factor: 94.444

10.  Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes.

Authors:  Valentina Bangiyeva; Ava Rosenbloom; Ashlynn E Alexander; Bella Isanova; Timothy Popko; Alan R Schoenfeld
Journal:  BMC Cancer       Date:  2009-07-14       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.